招银国际表研究报告指，康方生物(09926.HK) 2024年业绩反映强劲的成本控制，尽管销售收入未达预期。期内总收入为21亿元人民币，其中产品销售收入20亿元人民币，按年增长25%，净亏损为5亿元人民币。
该行预计，康方生物今年的产品销售将按年增长60%至33亿元人民币，受惠今年初AK104和AK112被纳入中国国家医保。该行将其目标价上调至102.61元，维持“买入”评级。(ca/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-02 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.